The present invention relates to the use of type 2 cytokines and mucins for increasing the amount or activity of bacterial species of the Clostridia class in the gastrointestinal tract, for treating dysbiosis in the gastrointestinal tract, for treating gastrointestinal and inflammatory disorders, and for promoting wound healing in the gastrointestinal tract.